p53: Biology and role for cellular radiosensitivity

Strahlentherapie und Onkologie

Volumn 176, Issue 6, 2000, Pages 278-285

  Dahm Daphi, Jochen ^a  

^a UNIVERSITY OF HAMBURG   (Germany)

Author keywords

Apoptosis; DSB; Exonuclease; G1 arrest; Irradiation; p53; Radiotherapy; Recombination; Tumor; X rays

Indexed keywords

PROTEIN P53;

APOPTOSIS; ARTICLE; CHROMOSOME 17P; DNA REPAIR; GENETIC RECOMBINATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; RADIOSENSITIVITY; SOLID TUMOR;

EID: 0034093941     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s000660050010     Document Type: Article

References (126)

1. Abend M, van Beuningen D. Bedeutung apoptotischer Prozesse für die Strahlentherapie. Teil II. Strahlenther Onkol 1998;174:212-6.
2. Adell G, Sun X-F, Stal O, et al. p53 status: an indicator for the effect of preoperative radiotherapy of rectal cancer. Radiother Oncol 1999;51:169-74.
3. Amundsen SA, Myers TG, Fornace AJ. Roles for repair in growth arrest and apoptosis: putting on the brakes after genotoxic stress. Oncogene 1998;17:3287-99.
4. Bakalkin G, Yakovleva T, Selivanova G, et al. p53 binds single-stranded DNA ends and catalyzes DNA renaturation and strand transfer. Proc Natl Acad Sci USA 1994;91:413-7.
5. Balcer-Kubiczek EK, Yin J, Harrison GH, et al. p53 mutational status and survival of human breast cancer MCF-7 cell variants after exposure to X-rays or fission neutrons. Radiat Res 1995;142:256-62.
6. Blandino G, Levine A, Oren M. Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 1999;18:477-86.
7. Bogue MA, Zhu C, Aguilar-Cordova E, et al. p53 is required for both radiation-induced differentiation and rescue of V(D)J rearrangement in seid mouse thymocytes. Genes Developm 1996;10:553-65.
8. Bouffler SD, Kemp CJ, Balmain A, et al. Spontaneous and ionizing radiation-induced chromosomal abnormalities in p53-deficient mice. Cancer Res 1995;55:3883-9.
9. Brachman DG, Beckett M, Graves D, et al. p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines. Cancer Res 1993;53:3667-9.
10. Bristow RG, Jang A, Peacock J, et al. Mutant p53 increases radioresistance in rat embryo fibroblasts simultaneously transfected with HPV16-E7 and/or activated H-ras. Oncogene 1994;9:1527-36.
11. Bristow RG, Benchimol S, Hill RP. The p53 gene as a modifier of intrinsic radiosensitivity: implications for radiotherapy. Radiother Oncol 1996;40:197-223.
12. Bristow RG, Hu Q, Jang A, et al. Redioresistant MTp53-expressing rat embryo cell transformants exhibit increased DNA-dsb rejoining during exposure to ionizing radiation. Oncogene 1998;16:1789-802.
13. Brown JM, Wouters BG. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res 1999;59:1391-9.
14. Chai Y, Cui J-Q, Shao N, et al. The second BRCT domain of BRCA1 proteins interacts with p53 and stimulates transcription from the p21 WAF1/CIP1 promoter. Oncogene 1999;18:263-8.
15. Cho Y, Gorina S, Jeffrey PD, et al. Crystal structure of a tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 1994;265:346-55.
16. Clarke AR, Purdie CA, Harrison DJ, et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 1993;362:849-52.
17. Coates PJ, Save V, Ansari B, et al. Demonstration of DNA damage/repair in individual cells using in situ end labelling: association of p53 with sites of DNA damage. J Pathol 1995;176:19-26.
18. Cross SM, Sanchez CA, Morgan CA, et al. A p53-dependent mouse spindel checkpoint. Science 1995;267:1353-6.
19. DeWeese TL, Walsh JC, Dillehay LE, et al. Human papillomavirus E6 and E7 oncoproteins alter cell cycle progression but not radiosensitivity of carcinoma cells treated with low-dose-rate radiation. Int J Radiat Oncol Biol Phys 1997;37:145-54.
20. Di Leonardo A, Linke SP, Clarkin K, et al. DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Developm 1994;8:2540-51.
21. DiBiase SJ, Guan J, Curran W, et al. Repair of DNA double-strand breaks and radiosensitivity to killing in an isogenic group of p53 mutant cell lines. Int J Radiat Oncol Biol Phys 1999;45:743-51.
22. Dudenhoffer C, Rohaly G, Will K, et al. Specific mismatch recognition in heteroduplex intermediates by p53 suggests a role in fidelity control of homologous recombination. Mol Cell Biol 1998;18:5332-42.
23. Dutta A, Ruppert M, Aster JC, et al. Inhibition of DNA replication factor RPA by p53. Nature 1993;365:79-82.
24. Ebara T, Mitsuhashi N, Saito Y, et al. Prognostic significance of immunohistochemically detected p53 protein expression in stage IIIB squamous cell carcinoma of the uterine cervix treated with radiation therapy alone. Gynecol Oncol 1997;63:216-8.
25. El-Deiry WS, Harper JW, O'Connor PM, et al. WAF1/CIP1 is induced in p53-mediated Glarrest and apoptosis. Cancer Res 1994;54:1169-74.
26. Ellis PA, Lonning PE, Borresen-Dale A, et al. Absence of p21 expression is associated with abnormal p53 in human breast carcinomas. Br J Cancer 1997;76:480-5.
27. Falette N, Paperin M-P, Treilleux I, et al. Prognostic value of p53 gene mutations in a large series of node-negative breast cancer patients. Cancer Res 1998;58:1451-5.
28. Ford JM, Hanawalt PC. Li-Fraumeni syndrome fibroblasts homozygous for p53 mutations are deficient in global DNA repair but exhibit normal transcription-coupled repair and enhanced UV resistance. Proc Natl Acad Sci USA 1995;92:8876-80.
29. Freedman DA, Levine AJ. Regulation of the p53 protein by the MDM2 oncoprotein - thirty-eight G.H.A. clowes memorial award lecture. Cancer Res 1999;59:1-7.
30. Pritsche M, Haessler C, Brandner G. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene 1993;8:307-18.
31. Gallardo D, Drazan KE, McBride WH. Adenovirus-based transfer of wild-type p53 gene increases ovarian tumor radiosensitivity. Cancer Res 1996;56:4891-3.
32. Geng L, Walter S, Melian E, et al. Transfection of a vector expressing wild-type p53 into cells of two human glioma cell lines enhances radiation toxicity. Radiat Res 1998;150:31-7.
33. Giaccia AJ, Kastan MB. The complexity of p53 modulation: emerging pattern from divergent signals. Genes Developm 1998;12:2973-83.
34. Gobert C, Skladanowski A, Larsen AK. The interaction between p53 and topoisomerase I is regulated differently in cells with wild-type and mutant p54. Proc Natl Acad Sci USA 1999;9618:10355-60, 1815-23.
35. Greenblatt MS, Bennett WP, Hollstein M, et al. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54:4855-78.
36. Grignon DJ, Caplan R, Sarkar FH, et al. p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610. J Natl Cancer Inst 1997;89:158-65.
37. Hashimoto T, Tokuchi M, Hayashi M, et al. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas. Cancer Res 1999;59:5572-7.
38. Hayakawa K, Mitsuhashi N, Hasegawa M, et al. The prognostic significance of immunohistochemically detected p53 protein expression in non-small cell lung cancer treated with radiation therapy. Anticancer Res 1998;18:3685-8.
39. Hedge PU, Brenski AC, Caldarelli DD, et al. Tumor angiogenesis and p53 mutations: prognosis in head and neck cancer. Arch Otolaryngol Head Neck Surg 1998;124:80-5.
40. Heise C, Sampson-Johannes A, Williams A, et al. ONYX-015, an E1B gene-attenuated adenovirus causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nature Med 1997;3:639-45.
41. Hermeking H, Lengauer C, Polyak K, et al. 14-3-3s is a p53-regulated inhibitor of G2/M progression. Mol Cell 1997;1:3-11.
42. Honda K, Sbisà E, Tullo A, et al. p53 mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumor ablation. Br J Cancer 1998;77:776-82.
43. Honkoop AH, van Diest PJ, de Jong JS, et al. Prognostic value of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. Br J Cancer 1998;77:621-6.
44. Huang H, Li C-Y, Little JB. Abrogation of p53 function by transfection of HPV16 E6 gene does not enhance resistance of human tumor cells to ionizing radiation. Int J Radiat Biol 1996;70:151-60.
45. Hwang A, Muschel RJ. Radiation and the G2 phase of the cell cycle. Radiat Res 1998;150:S52-9.
46. Janus FAN, Knippschild U, Wiesmüller L, et al. Different regulation of the p53 core domain activities 3′-to-5′exonuclease and sequence-specific DNA binding. Mol Cell Biol 1999;19:2155-68.
47. Jimenez GS, Bryntesson F, Torres-Arzayus MI, et al. DNA-dependent protein kinase is not required for p53-dependent response to DNA damage. Nature 1999;400:81-3.
48. Jung M, Notario V, Dritschilo A. Mutations in the p53 gene in radiation-sensitive and -resistant human squamous carcinoma cells. Cancer Res 1992;52:6390-3.
49. Kao GD, McKenna WG, Maity A, et al. Cyclin B1 availability is a rate-limiting component of the radiation-induced G2 delay in HeLa cells. Cancer Res 1997;57:753-8.
50. Kastan MB, Zhan Q, El-Deiry WS, et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 1992;71:587-97.
51. Koch WM, Brennan JA, Zahurak M, et al. p53 mutations and locoregional treatment failure in head and neck squamous cell carcinoma. J Natl Cancer Inst 1996;88:1580-6.
52. Komarov PG, Komarova EA, Kondratov RV, et al. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 1999;285:1733-7.
53. Komarova EA, Chernov MV, Franks R, et al. Transgenic mice with p53 responsive lacZ: p53 activity varies dramatically during normal development and determines radiation and drug sensitivity in vivo. EMBO 1997;16:1391-400.
54. Korkolopoulou P, Christodoulou P, Kouzelis K, et al. MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor. Br J Cancer 1997;75:1269-78.
55. Kuerbitz SJ, Plunkett BS, Walsh WV, et al. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 1992;89:7491-5.
56. Lakin ND, Hann BC, Jackson SP. The ataxia-telangiectasia related protein ATR mediates DNA-dependent phosphorylation of p53. Oncogene 1999;18:3989-95.
57. Leiter LM, Chen JMT, Tanaka M, et al. Loss of transactivation and transrepression function , and not RPA binding alters growth suppression by p53. Oncogene 1996;12:2661-8.
58. Li C-Y, Nagasawa H, Dahlberg WK, et al. Diminished capacity for p53 in mediating a radiation-induced G1 arrest in established human tumor cell lines. Oncogene 1995;11:1885-92.
59. Li R, Waga S, Hannon GJ, et al. Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature 1994;371: 534-7.
60. Linke SP, Clarkin KC, Wahl GM. p53 mediates permanent arrest over multiple cell cycles in response to gamma-irradiation. Cancer Res 1997;57:1171-9.
61. Lowe SW, Bodis S, McClatchey A, et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994;266:807-10.
62. Lu X, Lane DP. Differential induction of transcriptionally active p53 following UV or ionizing radiation: defects in chromosome instability syndromes? Cell 1993;75:765-78.
63. MacCallum PE, Hupp TR, Midgley CA, et al. The p53 response to ionizing radiation in adult and developing murine tissues. Oncogene 1996;13: 2757-587.
64. Madden SL, Galella EA, Riley D, et al. Induction of cell growth regulatory genes by p53. Cancer Res 1996;56:5384-90.
65. Maebayashi K, Mitsuhashi N, Takahashi T, et al. p53 mutation decreased radiosensitivity in rat yolk sac tumor cell lines. Int J Radiat Oncol 1999;44:677-82.
66. Mallya SM, Sikpi MO. Requirement for p53 in ionizing-radiation-inhibition of double-strand-break rejoining by human lymphoblasts. Mutat Res 1999;434:119-32.
67. Marmorstein LY, Ouchi T, Aaronson SA. The BRCA2 gene product functionally interacts with p53 and RAD51. Proc Natl Acad Sci USA 1998;95:13869-74.
68. May P, May E. Twenty years of p53 research: structural and functional aspects of the p53 protein. Oncogene 1999;18:7621-36.
69. McIlwrath AJ, Vasey PA, Ross GM, et al. Cell cycle arrest and radiosensitivity of human tumor cell lines: Dependence on Wild-type p53 for radiosensitivity. Cancer Res 1994;54:3718-22.
70. Mekeel KL, Tang W, Katchnic LA, et al. Inactivation of p53 results in high rates of homologous recombination. Oncogene 1997;14:1847-57.
71. Mineta H, Borg A, Dictor M, et al. p53 mutation, but not p53 overexpression, correlates with survival in head and neck squamous cell carcinoma. Br J Cancer 1998;78:1084-90.
72. Mirzayans R, Aubin RA, Bosnich W, et al. Abnormal pattern of postgamma-ray DNA replication in radioresistant fibroblast strains from affected members of a cancer-prone family with Li-Fraumeni syndrome. Br J Cancer 1995;71:1221-30.
73. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995;80:293-9.
74. Miyashita TKS, Krajewska M, Wang HG, et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994;9:1799-805.
75. Nakano T, Oka K, Ishikawa A et al. Immunohistocehemical prediction of radiation response and local control in radiation therapy for cervical cancer. Cancer Detect Prevent 1998;22:120-8.
76. Ng CE, Banerjee SK, Pavliv M, et al. p53 status, cellular recovery and cell cycle arrest as prognosticators of in vitro radiosensitivity in human pancreatic adenocarcinoma cell lines. Int J Radiat Biol 1999;75:1365-76.
77. O'Connor PM, Jackman J, Bae I, et al. Characterization of the p53 tumor suppressor pathway in cell lines of the national cancer institute anticancer drug screen and correlations with the growth-inhibitor potency of 123 anticancer agents. Cancer Res 1997;57:4285-300.
78. Ogiwara H, Nakamura T, Baba S. Variables related to risk of recurrence in rectal cancer without lymph node metastasis. Ann Surg Oncol 1994;1:99-104.
79. Pai HH, Rochon L, Clark B, et al. Overexpression of p53 protein does not predict local-regional control or survival in patients with early-stage squamous cell carcinoma of the glottic larynx treated with radiotherapy. Int J Radiat Oncol Biol Phys 1998;41:37-42.
80. Pellegata NS, Antoniono RJ, Redpath JL, et al. DNA damage and p53-mediated cell cycle arrest: A reevaluation. Proc Natl Acad Sci USA 1996;93:15209-14.
81. Petersen S, Thames HD, Nieder C, et al. The results of colorectal cancer treatment by p53 status: A treatment-specific overview. Radiother Oncol (submitted).
82. Pfeifer GP, Holmquist GP. Mutagenesis in the p53 gene. Biochim Biophys Acta 1997;1333:M1-8.
83. Pollack A, Zagars GZ. Radiotherapy for stage T3b transitional cell carcinoma of the bladder. Semin Urol Oncol 1996;14:86-95.
84. Pollack IF, Hamilton RL, Finkelstein SD, et al. The relationship between Tp53 mutations and overexpression of p53 and prognosis in malignant gliomas of childhood. Cancer Res 1997;57:304-9.
85. Polyak K, Xia Y, Zweier JL, et al. A model for p53-induced apoptosis. Nature 1997;389:300-5.
86. Railo-M, Lundin J, Haglund C, et al. Ki 67, p53, ER-receptors, ploidy and S-phase as prognostic factors in T1 node negative breast cancer. Acta Oncol 1997;36:369-74.
87. Raybaud-Diogene HF, Fortin A, Morency R, et al. Markers of radioresistance in squamous cell carcinomas of the head and neck: a clinicopathologic and immunohistochemical study. J Clin Oncol 1997;15:1030-8.
88. Ribeiro JCC, Barnetson AR, Fisher RJ, et al. Relationship between radiation response and p53 status in human bladder cancer cells. Int J Radiat Biol 1997;72:11-20.
89. Ribeiro U, Finkelstein SD, Safatle-Ribeiro AV, et al. p53 sequence analysis predicts treatment response and outcome of patients with esophageal carcinoma. Cancer 1998;83:7-18.
90. Riva C, Lavielle JP, Reyt E, et al. Differential c-Myc, c-jun, c-raf and p53 expression in squamous cell carcinoma of the head and neck: implications in drug and radioresistance. Eur J Oral Oncol 1995;31B:384-91.
91. Roychowdhury DF, Tseng A, Fu KK, et al. New prognostic factors in nasopharyngeal carcinoma. Tumor angiogenesis and C-erbB2. Cancer 1996; 77:1419-26.
92. Russell KJ, Wiens LW, Deniers GW, et al. Abrogation of the G2 Checkpoint results in differential radiosensitization of G1 checkpoint-deficient and G1 checkpoint-competent cells. Cancer Res 1995;55:1639-42.
93. Scherer SJ, Welter C, Zang K-D, et al. Specific in vitro binding of p53 to the promoter region of the human mismatch repair gene hMSH2. Biochem Biophys Res Commun 1996;221:722-8.
94. Schwartz JL, Rasey J, Jordan R, et al. Functional inactivation of p53 by HPV-E6 transformation is associated with a reduced expression of radiation-induced potentially lethal damage. Int J Radiat Biol 1999;75:285-91.
95. Servomaa K, Kiuru A, Grenman R, et al. p53 mutations associated with increased sensitivity to ionizing radiation in human head and neck cancer cell lines. Cell Proliferat 1996;29:219-30.
96. Shaulsky G, Ben Ze'ev A, Rotter V. Subcellular distribution of the p53 protein during the cell cycle of Balb/c 3T3 cells. Oncogene 1990;5:1707-11.
97. Shimada A, Kato S, Enjo K, et al. The transcriptional activities of p53 and its homologue p51/p63: similarities and differences. Cancer Res 1999;59:2781-6.
98. Siles E, Villalobos M, Valenzuela MT, et al. Relationship between p53 status and radiosensitivity in human tumor cell lines. Br J Cancer 1996; 73:581-8.
99. Silvestrini R, Veneroni S, Daidone MG, et al. The bcl-2 protein, a prognostic indicator strangely related to p53 protein in Lymph node-negative breast cancer patients. J Natl Cancer Inst 1994;86:499-504.
100. Silvestrini R, Veneroni S, Benini E, et al. Expression of p53, glutathione s-transferase-tt, and bcl-2 proteins and benefit from adjuvant radiotherapy in breast cancer. J Natl Cancer Inst 1997;89:639-45.
101. Slichenmyer WJ, Nelson WG, Slebos RJ, et al. Loss of a p53-associated G1 checkpoint does not decrease cell survival following DNA damage. Cancer Res 1993;53:4164-8.
102. Srivastava S, Wang S, Tong YA, et al. Several mutant proteins detected in cancer-prone families with Li-Fraumeni syndrome exhibit transdominant effects on the biochemical properties of the wild-type p53. Oncogene 1993;8:2449-56.
103. Steward N, Hicks GG, Paraskevas F, et al. Evidence for a second cell cycle block at G2/M by p53. Oncogene 1995;10:109-15.
104. Stommel JM, Marchenko ND, Jiminez GJ, et al. A leucin-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking. EMBO 1999;18:1660-72.
105. Stürzbecher H-W, Donzelmann B, Henning W, et al. p53 is linked directly to homologous recombination processes via RAD51/RecA protein interaction. EMBO 1996;15:1992-2002.
106. Tang W, Willers H, Powell SN. p53 directly enhances rejoining of DNA double-strand breaks with cohesive ends in g-irradiated mouse fibroblasts. Cancer Res 1999;59:2562-5.
107. Taylor WR, Agarwal ML, Agarwal A, et al. p53 inhibits entry into mitosis when DNA synthesis is blocked. Oncogene 1999;18:283-95.
108. Tchang F, Mechali M. Nuclear import of p53 during Xenopus laevis early development in Relation to DNA Replication and DNA repair. Exp Cell Res 1999;251:46-56.
109. Tomizia Y, Kohno T, Fujita T, et al. Correlation between the status of p53 gene and survial in patients with stage I non-small cell lung carcinoma. Oncogene 1999;18:1007-14.
110. Tsang N-M, Nagasawa H, Li C, et al. Abrogation of p53 function by transfection of HPV16E6 gene enhances the resistance of human diploid fibroblasts to ionizing radiation. Oncogene 1995;10:2403-8.
111. Varley JM, Evans DGR, Birch JM. Li-Fraumeni syndrome - a molecular and clinical review. Br J Cancer 1997;76:1-14.
112. Wang WW, Vermeulen W, Coursen JD, et al. The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway. Genes Developm 1996;10:1219-32.
113. Wiesmüller L, Cammenga J, Deppert W. In vivo assay of p53 function in homologous recombination between Simian Virus 40 chromosomes. J Virol 1996;70:3737-44.
114. Wiggenraad R, Tamminga R, Blok P, et al. The prognostic significance of p53 expression for survival and local control in rectal carcinoma treated with surgery and postoperative radiotherapy. Int J Radiat Oncol Biol Phys 1998;41:29-35.
115. Will K, Warnecke G, Wiesmüller L, et al. Specific interaction of mutant p53 with regions of matrix attachment region DNA elements (MARs) with a high potential for base unpairing. Proc Natl Acad Sci USA 1998;95:13681-6.
116. Willers H, McCarthy EE, Wu B, et al. Dissociation of p53-mediated suppression of homologous recombination from cell cycle checkpoint control. Oncogene (submitted).
117. Williams KJ, Boyle JM, Birch JM, et al. Cell cycle arrest defect in Li-Fraumeni syndrome: a mechanism of cancer predisposition? Oncogene 1997;14:277-82.
118. Wong CS, Tsao MS, Sharma V, et al. Prognostic role of p53 protein expression in epidermoid carcinoma of the anal canal. Int J Radiat Oncol Biol Phys 1999;45:309-14.
119. Woo RA, McLure KG, Lees-Miller SP, et al. DNA-dependent protein kinase acts upstream of p53 in response to DNA damage. Nature 1998;394:700-4.
120. Wu CS, Pollack ACB, Chyle V, et al. Prognostic value of p53 in muscle-invasive bladder cancer treated with preoperative radiotherapy. Urology 1996;47:305-10.
121. Xu C, Meikranzt W, Schlegel R, et al. The human papilloma virus 16E6 gene sensitizes human mammary epithelial cells to apoptosis induced by DNA damage. Proc Natl Acad Sci USA 1995;92:7829-33.
122. Yount GL, Haas-Kogan DA, Vidair CA, et al. Cell-cycle synchrony unmasks the influence of p53 function on radiosensitivity of human glioblastoma cells. Cancer Res 1996;56:500-6.
123. Zaffaroni N, Benini E, Gornati D, et al. Lack of a correlation between p53 protein expression and radiation response in human tumor primary cultures. Stem Cells 1995;13:77-85.
124. Zhang H, Somasundaram K, Peng Y, et al. BRCA1 physically associates with p53 and stimulates its transcriptional activity. Oncogene 1998;16:1713-21.
125. Zhu J, Zhou W, Chen X. Identification of a novel p53 functional domain that is necessary for mediating apoptosis. J Biol Chem 1998;273:13030-6.
126. Zhu J, Jiang J, Zhou W, et al. The potential tumor suppressor p73 differentially regulates cellular p53 target genes. Cancer Res 1998;58:5061-5.